CN Mobile Logo



Immunotherapy Combination Active in Advanced Melanoma

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.


The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Treatment with nab­-paclitaxel resulted in significantly improved progression-free survival and a greater disease control rate in chemotherapy-naive patients with metastatic melanoma compared with dacarbazine.

Neither GM-CSF nor peptide vaccination, thought to contribute to antitumor responses, improved survival outcomes in patients with high-risk resected melanoma.

In the real-world setting, about one-third of melanoma patients treated with ipilimumab had grade 3 or worse immune-related adverse events.

Metastasis to sentinel lymph nodes was significantly lower among patients with melanoma with histologic regression of their disease compared with those without regression.

Results of a new study have indicated that the risk of developing melanoma may be almost doubled among certain survivors of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Results of a study suggest that durable survival is possible in melanoma patients treated with MAPK inhibitors, and is perhaps similar to the survival observed with ipilimumab.


Subscribe to Melanoma on [sitename]
  • When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, D, and E of skin cancer—asymmetry, border, color, diameter, and evolving.

By clicking Accept, you agree to become a member of the UBM Medica Community.